Journal
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
Volume 260, Issue -, Pages S111-S115Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00406-010-0156-4
Keywords
Dementia; Risk; Anticholinergic drugs
Categories
Funding
- German Competence Network on Dementia (CND)
- German Federal Ministry for Education and Research [O1 GI 0102, 01 GI 0710, 01 GI 0711, 01 GI 0712, 01 GI 0713, 01 GI 0714, 01 GI 0715, 01 GI 0716, 01 GI 0717]
- Federal Institute for Drugs and Medical Devices (Bundesinstitut fur Arzneimittel und Medizinprodukte, BfArM) [V-9909/68502/2008]
- Pfizer
- Esai
- Janssen Cilag
- Novarits
- Talecris
- Altana Pharma
- Octapharma
- Merz
- AC Immune
- Organon
- Bayer
- Lundbeck
- Wyeth
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- Bohringer
- Schering
- Sanofi Aventis
- Merck
Ask authors/readers for more resources
An increasing number of longitudinal cohort studies have identified a risk increase for dementia by the chronic use of drugs with anticholinergic properties. The respective data from the German Study on Aging, Cognition and Dementia in Primary Care Patients (AgeCoDe) also showing risk increase (hazard ratio = 2.081) are reported here. The mechanisms by which the risk increase is transported are still unknown. Irritation of compensated alterations of cholinergic transmission at the pre-dementia stage of Alzheimer's disease (AD) or acceleration of neuroinflammation by disturbance of the anti-inflammatory effect of cholinergic innervation are discussed. In terms of dementia prevention, centrally acting anticholinergic drugs should be strictly avoided, because of long-term dementia risk increase in addition to acute negative effects on cognition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available